Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Suvorexant

FDA-approved product (tablet, oral), marketed as Belsomra.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Suvorexant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Orexin receptor antagonists
FDA pharmacologic class
Orexin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Suvorexant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Suvorexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

    NCT07214207 · start 2025-12-04

    Registered record
    Registry ID
    NCT07214207
    Conditions
    Alcohol Use Disorder
    Interventions
    Suvorexant 10 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-04
    Completion
    2030-09
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionSuvorexant 10 mg; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

    NCT06655883 · start 2025-10-09

    Registered record
    Registry ID
    NCT06655883
    Conditions
    Insomnia
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-10-09
    Completion
    2027-06-24
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionSuvorexant; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

    NCT06854224 · start 2025-09-01

    Registered record
    Registry ID
    NCT06854224
    Conditions
    Suicide Risk; Major Depressive Disorder (MDD)
    Interventions
    Suvorexant (dual orexin receptor antagonist)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2027-07-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuicide Risk; Major Depressive Disorder (MDD)
    InterventionSuvorexant (dual orexin receptor antagonist)
    PhasePhase 2
    Registry statusRecruiting

  • Suvorexant for Treatment of AUD and PTSD

    NCT06679062 · start 2025-07-16

    Registered record
    Registry ID
    NCT06679062
    Conditions
    Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD); Insomnia
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-16
    Completion
    2027-03
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD); Insomnia
    InterventionSuvorexant; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

    NCT06484075 · start 2024-11-21

    Registered record
    Registry ID
    NCT06484075
    Conditions
    Healthy Volunteers; Alcohol Use Disorder (AUD)
    Interventions
    Placebo; Suvorexant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-11-21
    Completion
    2029-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers; Alcohol Use Disorder (AUD)
    InterventionPlacebo; Suvorexant
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

    NCT06162663 · start 2024-09-20

    Registered record
    Registry ID
    NCT06162663
    Conditions
    Breast Cancer; Insomnia
    Interventions
    Suvorexant Tablets; Placebo Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2024-09-20
    Completion
    2026-02-17
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Insomnia
    InterventionSuvorexant Tablets; Placebo Control
    PhasePhase 4
    Registry statusTerminated

  • Suvorexant and Alcohol

    NCT06326684 · start 2024-06-07

    Registered record
    Registry ID
    NCT06326684
    Conditions
    Alcohol Use Disorder
    Interventions
    Alcohol; Placebo; Suvorexant; Suvorexant
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2024-06-07
    Completion
    2027-03-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionAlcohol; Placebo; Suvorexant; Suvorexant
    PhaseEarly phase 1
    Registry statusRecruiting

  • Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

    NCT05908526 · start 2023-10-09

    Registered record
    Registry ID
    NCT05908526
    Conditions
    Insomnia
    Interventions
    Baseline surveys, Cognitive testing and EMAs; Actiwatch; suvorexant (or placebo); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-10-09
    Completion
    2024-08-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionBaseline surveys, Cognitive testing and EMAs; Actiwatch; suvorexant (or placebo); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Trial of Suvorexant for Sleep in Children With Autism

    NCT05546554 · start 2023-08-09

    Registered record
    Registry ID
    NCT05546554
    Conditions
    Autism; Autism Spectrum Disorder
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-08-09
    Completion
    2028-02-28
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism; Autism Spectrum Disorder
    InterventionSuvorexant; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Measuring Acute Drug Demand in Humans

    NCT05829655 · start 2023-08-08

    Registered record
    Registry ID
    NCT05829655
    Conditions
    Opioid Use Disorder; Opioid Dependence
    Interventions
    Drug A (Blinded Drug); Drug B (Blinded Drug); Drug C (Blinded Drug); Drug D (Blinded Drug); Suvorexant (20mg/day); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2023-08-08
    Completion
    2028-01-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Opioid Dependence
    InterventionDrug A (Blinded Drug); Drug B (Blinded Drug); Drug C (Blinded Drug); Drug D (Blinded Drug) +2 more
    PhaseEarly phase 1
    Registry statusRecruiting

  • Efficacy of Suvorexant on Post-operative Sleep Disturbance

    NCT05823844 · start 2023-05-01

    Registered record
    Registry ID
    NCT05823844
    Conditions
    Postoperative Insomnia; Postoperative Delirium
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-05-01
    Completion
    2025-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Insomnia; Postoperative Delirium
    InterventionSuvorexant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

    NCT05711862 · start 2023-03-09

    Registered record
    Registry ID
    NCT05711862
    Conditions
    Methamphetamine Use Disorder
    Interventions
    suvorexant (SUVO); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-03-09
    Completion
    2024-03-28
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethamphetamine Use Disorder
    Interventionsuvorexant (SUVO); Placebo
    PhasePhase 2
    Registry statusTerminated

  • Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

    NCT05593653 · start 2023-01-06

    Registered record
    Registry ID
    NCT05593653
    Conditions
    Insomnia; Metabolic Health; Menopause
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-01-06
    Completion
    2025-10-24
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Metabolic Health; Menopause
    InterventionSuvorexant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Suvorexant for Opioid/Stimulant Co-use

    NCT05546515 · start 2022-12-01

    Registered record
    Registry ID
    NCT05546515
    Conditions
    Opioid Use Disorder; Stimulant Use Disorder
    Interventions
    Suvorexant (dual orexin receptor antagonist); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-12-01
    Completion
    2024-11-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Stimulant Use Disorder
    InterventionSuvorexant (dual orexin receptor antagonist); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

    NCT05656534 · start 2022-11-29

    Registered record
    Registry ID
    NCT05656534
    Conditions
    Alcohol Use Disorder
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2022-11-29
    Completion
    2024-08-01
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionSuvorexant; Placebo
    PhaseEarly phase 1
    Registry statusCompleted